Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells.

@article{Fiskus2013DualPI,
  title={Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells.},
  author={Warren Fiskus and Srdan Verstovsek and Taghi Manshouri and Jacqueline E. Smith and Karissa Peth and Sunil H Abhyankar and Joseph McGuirk and Kapil N. Bhalla},
  journal={Molecular cancer therapeutics},
  year={2013},
  volume={12 5},
  pages={577-88}
}
Hemopoietic progenitor cells (HPC) from myeloproliferative neoplasms (MPN) such as myelofibrosis commonly express mutant JAK2-V617F or other mutations that are associated with increased activities of JAK-STAT5/3, RAS/RAF/MAPK, and PI3K/AKT/mTOR pathways. This confers proliferative and survival advantage on the MPN HPCs. Treatment with JAK tyrosine kinase inhibitor (TKI), for example, TG101209, TG101348 (SAR302503), or INCB018424 (ruxolitinib), inhibits mutant JAK2-mediated signaling. Although… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

Inhibition of autophagy enhances effects of PF-04691502 on apoptosis and DNA damage of lung cancer cells.

The international journal of biochemistry & cell biology • 2016
View 2 Excerpts

Myeloproliferative Neoplasms: Molecular Drivers and Therapeutics.

Progress in molecular biology and translational science • 2016
View 1 Excerpt

Similar Papers

Loading similar papers…